SCHEMBL2642653

SCHEMBL2642653

CC(=O)Nc1csc(C)n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ADORA3 P0DMS8 3/20 0.41
ADORA2A P29274 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PIK3CG P48736 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
DYRK1A Q13627 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21695368 0.86 GRM5 (0.45) GRM5L3MBTL1SMN1; SMN2KMT2APOLB
SCHEMBL27315164 0.85 POLB (0.47) SMN1; SMN2KMT2APOLBKDM4EMAPT
SCHEMBL21695367 0.81 GRM5 (0.42) GRM5L3MBTL1SMN1; SMN2KMT2AKDM4E
SCHEMBL18236169 0.81 GRM5 (0.42) GRM5SMN1; SMN2NPC1RAB9A
SCHEMBL11358850 0.80 L3MBTL1 (0.48) L3MBTL1SMN1; SMN2KMT2APOLBKDM4E
SCHEMBL11350463 0.80 L3MBTL1 (0.62) L3MBTL1SMN1; SMN2KMT2APOLBKDM4E
SCHEMBL2645328 0.79 SMN1; SMN2 (0.57) GRM5SMN1; SMN2KMT2AKDM4EADORA3
SCHEMBL26880886 0.79 ADORA1 (0.45) GRM5L3MBTL1SMN1; SMN2POLBLMNA
SCHEMBL26882860 0.79 CYP1A2 (0.41) GRM5SMN1; SMN2KMT2AKDM4EADORA3
SCHEMBL2642608 0.78 L3MBTL1 (0.43) L3MBTL1SMN1; SMN2KMT2APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4132798-A ANTIULCER, ANTISECRETORY JOHN WYETH & BROTHER LTD. (GB) 1979-01-02 US claimed
WO-2021180235-A1 INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF 四川海思科制药有限公司 2021-09-16 WO disclosed
US-8765789-B2 2-pyridinecarboxamide derivatives MSD K.K. (JP) 2014-07-01 US disclosed
US-20130085156-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES MSD K.K. (JP) 2013-04-04 US disclosed
US-8344003-B2 2-pyridinecarboxamide derivatives MSD K. K. (JP) 2013-01-01 US disclosed
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES MSD K.K. (JP) 2010-02-18 US disclosed
US-7629362-B2 2-pyridine carboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 US disclosed
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-16 US disclosed
EP-1598349-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-23 EP disclosed
US-4132798-A ANTIULCER, ANTISECRETORY JOHN WYETH & BROTHER LTD. (GB) 1979-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085156-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES GCKR, GCK, HK2 GRM5 1488/4885L3MBTL1 4342/4885SMN1; SMN2 4125/4885
US-20060258701-A1 Novel 2-pyridinecarboxamide derivatives GCKR, GCK, HK2 GRM5 1443/4885L3MBTL1 4359/4885SMN1; SMN2 4142/4885
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES GCKR, GCK, HK2 GRM5 1488/4885L3MBTL1 4342/4885SMN1; SMN2 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.